In­cyte says JAK cream clears PhI­II eczema tri­al in chil­dren, but an­a­lysts are still watch­ing safe­ty

On a long march to bring its top­i­cal JAK in­hibitor to the block­buster ranks, In­cyte is cel­e­brat­ing pos­i­tive re­sults from a Phase III tri­al in­volv­ing chil­dren.

The TRuE-AD3 study en­rolled pe­di­atric pa­tients be­tween the ages of 2 and 11 who have atopic der­mati­tis, and In­cyte re­port­ed that sig­nif­i­cant­ly more pa­tients treat­ed with Opzelu­ra — a cream for­mu­la­tion of rux­oli­tinib — achieved In­ves­ti­ga­tor’s Glob­al As­sess­ment Treat­ment Suc­cess com­pared to con­trol, which was a non-med­icat­ed cream.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER